Navigation Links
Patheon to Present New Updates in Drug Formulation and Bioavailability

(PRWEB) March 21, 2013

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that the company will present at a program titled “New Updates in Drug Formulation and Bioavailability” on April 9, 2013, organized jointly by Medicon Valley Alliance, KemiVärlden Biotech and Patheon.

A presentation “Solubility and Bioavailability Enhancement for Poorly Soluble Drugs” will be given by Anil Kane, Executive Director, Global Formulation Sciences, Patheon Inc. on Tuesday, April 9, 2013 at 1:35 p.m. Central European Time. For more information on upcoming events, visit

Patheon representatives will also be available to meet during the program, showcasing several of Patheon’s key service offerings, including SoluPath™ - an innovative and cost-effective service used to identify an optimal drug delivery system for compounds with poor bioavailability. In a recent case study, SoluPath™ improved bioavailability by four times in just three months. Learn more by visiting the company’s website at    

About Patheon

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.

Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 18 locations, including 14 commercial contract manufacturing facilities and 12 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Patheon to Present at 2013 DCAT Week
2. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
3. Patheon to Present at Informex USA
4. Patheon to Host Complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at Milton Park, UK Facility
5. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
6. Leading Photonics and Laser Researchers to Present Latest Work at SPIE Optics + Optoelectronics
7. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
8. 3D Biomatrix Announces Stipend to Present at Spring 2013 Conferences
9. De nouvelles données mettent en évidence le fardeau considérable que représente la nycturie
10. Palatin Technologies To Present At The 25th Annual ROTH Conference
11. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... in cat and human plaque and pave the way for ... health problems in cats     ... the most commonly diagnosed health problems in cats, yet relatively ... until now. Two collaborative studies have been conducted by researchers ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
Breaking Biology Technology:
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
Breaking Biology News(10 mins):